ADMAHealthcare · BiotechnologyThe 4 Wall Street analysts covering ADMA Biologics, Inc. hold a median 12-month price target of $18 — +66.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 3 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores ADMA Biologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ADMA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +66.8% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 July 2026 | Mizuho | Maintains | Outperform | $20 → $17 |
| 7 May 2026 | Canaccord Genuity | Maintains | Buy | $21 → $18 |
| 7 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 7 May 2026 | Mizuho | Maintains | Outperform | $24 → $20 |
| 7 May 2026 | Mizuho | Maintains | Outperform | — |
| 21 Apr 2026 | Canaccord Genuity | Initiates | Buy | — |
| 13 Apr 2026 | Mizuho | Maintains | Outperform | — |
| 26 Mar 2026 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 8 May 2025 | Raymond James | Maintains | Strong Buy | — |
| 4 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 8 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Nov 2024 | Raymond James | Maintains | Strong Buy | — |
| 14 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 12 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Aug 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 9 July 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 20 June 2024 | Mizuho | Maintains | Buy | — |
| 10 May 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 10 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ADMA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, ADMA Biologics, Inc. returned −28.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 44% of US stocks
Cheaper than 24% of US stocks
Cheaper than 15% of US stocks
Cheaper than 33% of US stocks
Higher than 32% of US stocks
Higher than 49% of US stocks
Higher than 82% of US stocks
Higher than 93% of US stocks
Higher than 91% of US stocks
Higher than 92% of US stocks
Higher than 99% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ADMA Biologics, Inc. has a market value of $2.5B and an enterprise value of $2.5B.
Revenue in the twelve months to 30 June 2026: $512.3M. The latest quarter grew 2.0% year on year.
Net income over the same four quarters: $169.0M, a 33.0% net margin.
Diluted earnings per share, trailing twelve months: $0.70.
Free cash flow in the twelve months to 30 June 2026: $116.2M.
ADMA Biologics, Inc. spent $187.2M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 15.7×; forward P/E: 11.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
ADMA Biologics, Inc. employs 640 people — $800K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ADMA Biologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ADMA Biologics raised its minimum full-year earnings expectations after third-quarter profit increased, supported by stronger ASCENIV sales and improved manufacturing yields. Competitive pressure weighed on BIVIGAM.
Why it matters — The update highlights stronger results and raised earnings expectations alongside continued competitive pressure on BIVIGAM.
ADMA Biologics reported third-quarter 2026 revenue of $141.1 million, up 5% year over year, with ASCENIV revenue up 31% to $124.7 million. GAAP net income rose 37% to $49.9 million; the company reiterated its fiscal 2026 revenue guidance and raised its adjusted earnings outlook.
Why it matters — The results highlight growth in ASCENIV sales and earnings alongside updated adjusted earnings expectations.
ADMA Biologics closed the recent trading day at $11.41, down 2.89% from the preceding trading day.
Why it matters — The report notes a decline in ADMA shares during the latest trading session.
Zacks Investment Research discusses whether brokerage analysts’ recommendations to buy, sell, or hold ADMA are useful to investors. The excerpt does not specify a rating change or recommendation for ADMA.
Why it matters — ADMA watchers may find the item relevant as it considers the role of analyst recommendations in investment decisions.
Zacks Investment Research reports that ADMA Biologics has recently been among the stocks most watched by Zacks.com users and says it is worth exploring what may lie ahead for the stock.
Why it matters — The item highlights recent user attention to ADMA but provides no further details about the company or its outlook.
The 4 Wall Street analysts covering ADMA Biologics, Inc. have a median 12-month price target of $18, with estimates ranging from $12 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering ADMA Biologics, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ADMA Biologics, Inc. 56 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, ADMA Biologics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +66.8% from the last close, and Ticker Nerd's factor model ranks ADMA Biologics, Inc. 56 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ADMA Biologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $21 over the next 12 months.
ADMA Biologics, Inc. returned -28.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing specialty plasma-derived biologics for patients with immune deficiencies and certain infectious diseases.
The most recent item we track (MarketBeat, 4 Nov 2026): "ADMA Biologics Q3 Earnings Call Highlights". ADMA Biologics raised its minimum full-year earnings expectations after third-quarter profit increased, supported by stronger ASCENIV sales and improved manufacturing yields. Competitive pressure weighed on BIVIGAM.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing specialty plasma-derived biologics for patients with immune deficiencies and certain infectious diseases. ADMA’s current portfolio includes FDA-approved immune globulin and hyperimmune products used to help treat primary humoral immunodeficiency, support immune-compromised patients, and provide protection in hepatitis B exposure settings. The company operates an integrated model that combines plasma collection, fractionation, purification, and commercialization, allowing it to support the supply of its therapies through its own manufacturing infrastructure. ADMA serves healthcare providers and patients in the United States and internationally, with a business centered on plasma-derived therapeutics and targeted immunology applications. Headquartered in Ramsey, New Jersey, ADMA Biologics plays a specialized role in the plasma medicines market by supplying niche biologic treatments for clinical use.
CEO Mr. Adam S. Grossman · 640 employees · United States · https://www.admabiologics.com
